Development and Preclinical Evaluation of [68Ga]Ga-DOTA-L3: A Novel PET Tracer for Quantitative Imaging of Carbonic Anhydrase IX
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5787-5798
DOI: 10.1021/acs.molpharmaceut.6c00836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 25.09.2026. Verfasst von Jie Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: North Sichuan Medical College, Sichuan637100, China. Hauptthemen laut MEDLINE: Carbonic Anhydrase IX, Gallium Radioisotopes, Radiopharmaceuticals, Antigens, Neoplasm. Die Arbeit nennt 44 Literaturangaben. Gefördert von: North Sichuan Medical College, Department of Science and Technology of Sichuan Province.
Abstract (Originalsprache)
Carbonic anhydrase IX (CA IX) is a key biomarker for tumor hypoxia and a promising target for molecular imaging. In this study, we developed [68Ga]Ga-DOTA-L3, a novel small-molecule CA IX-targeted PET tracer. The radiolabeling was optimized to consistently achieve a radiochemical purity of >98% (10 μg precursor, 90 °C, pH 4.5, 10 min), with excellent stability in saline and FBS up to 240 min. In vivo studies demonstrated rapid blood clearance and predominant renal excretion. Surface plasmon resonance analysis demonstrated high-affinity binding of the DOTA-L3 precursor toward CA IX (Kd = 7.60 ± 0.37 nM) with highest affinity observed for CA IX among the tested isoforms. MicroPET/CT imaging (30−240 min p.i.) showed robust tumor accumulation in OSRC-2 (SUVmean = 1.47 ± 0.21) and HT-29 (SUVmean = 1.03 ± 0.12) xenografts, while minimal uptake was observed in CA IX-low FTC-238 tumors (SUVmean = 0.21 ± 0.05) at 60 min p.i. PET-derived tumor uptake showed a strong linear correlation with CA IX expression levels (R2 = 0.976, P < 0.001) across the three tumor models. High tumor-to-muscle and tumor-to-blood ratios further confirm favorable imaging contrast (T/M = 27.53 ± 1.89 and T/B = 24.61 ± 2.35 at 240 min p.i. for OSRC-2 model). These results support [68Ga]Ga-DOTA-L3 as a promising candidate for non-invasive assessment of CA IX-associated hypoxia and as a scaffold for future theranostic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- North Sichuan Medical College, Sichuan637100, China.
- The Affiliated Hospital of North Sichuan Medical College, Sichuan637000, China.
- Nuclear Medicine and Radiation Safety Key Laboratory of Sichuan Province, North Sichuan Medical College, Sichuan637100, China.
- Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Sichuan637100, China.
ORCID-Profile: Jie Li
Förderung
- North Sichuan Medical College
- Department of Science and Technology of Sichuan Province
Zitieren
APA
Li, J., Luo, Y., Luo, C., Yang, Z., Luo, F., Gu, H., Chen, F., He, Z., & Li, S. (2026). Development and Preclinical Evaluation of [68Ga]Ga-DOTA-L3: A Novel PET Tracer for Quantitative Imaging of Carbonic Anhydrase IX. Molecular Pharmaceutics, 23(11), 5787-5798. https://doi.org/10.1021/acs.molpharmaceut.6c00836
Vancouver
Li J, Luo Y, Luo C, Yang Z, Luo F, Gu H, et al. Development and Preclinical Evaluation of [68Ga]Ga-DOTA-L3: A Novel PET Tracer for Quantitative Imaging of Carbonic Anhydrase IX. Molecular Pharmaceutics. 2026;23(11):5787-5798. doi:10.1021/acs.molpharmaceut.6c00836
BibTeX
@article{Li2026,
author = {Li, Jie and Luo, Yuhui and Luo, Chengyu and Yang, Zixin and Luo, Fei and Gu, Huajian and Chen, Fei and He, Zongxi and Li, Suping},
title = {Development and Preclinical Evaluation of [68Ga]Ga-DOTA-L3: A Novel PET Tracer for Quantitative Imaging of Carbonic Anhydrase IX},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5787--5798},
doi = {10.1021/acs.molpharmaceut.6c00836}
}
EUVIMED